# Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

> **NCT02137525** · PHASE2 · WITHDRAWN · sponsor: **INSYS Therapeutics Inc**

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** Morphine 6 mg
- **DRUG:** Fentanyl 100 µg
- **DRUG:** Fentanyl 200 µg
- **DRUG:** Fentanyl 400 µg
- **DRUG:** Placebo Sublingual Spray
- **DRUG:** Intravenous Placebo

## Key facts

- **NCT ID:** NCT02137525
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2017-06-29
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated
- **Last updated:** 2017-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137525, "Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02137525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*